An ad-hoc group of infectious disease doctors and health researchers on Tuesday held a public meeting to review recent ...

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

Currently, there is no vaccine that exists for RSV, and infants younger than 6 months old are too young to receive most vaccines recommended by the Centers for Disease Control and Prevention.

Pfizer’s RSV vaccine for pregnant people The FDA announced Wednesday it has agreed to review Pfizer’s vaccine candidate, RSVpreF, for approval and set an action date for August 2023.

I think it’s the expectation is that we will have licensed RSV vaccine sometime next year in 2023, probably in time for the peak season,” said Dr. Jason McLellan/Professor of Molecular ...

GSK will market its new product under the brand name “Arexvy.” The British pharmaceutical giant said it plans to launch its new vaccine before the 2023/2024 RSV season.

The 2023 version of the vaccine also will be designed against the latest dominant Omicron subvariant, XBB.1.5. It will be a monovalent vaccine focused only on XBB.

RSV, which stands for respiratory syncytial virus, kills about 14,000 older adults in the United States and leads to severe disease in about 58,000 to 80,000 infants.

By Mallika Marshall, MD October 31, 2022 / 5:38 PM EDT / CBS Boston BOSTON -- As RSV cases surge among children in New England, there could be hope on the horizon.